mTORC1 activity is essential for erythropoiesis and B cell lineage commitment.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 13 05 2019
accepted: 26 10 2019
entrez: 16 11 2019
pubmed: 16 11 2019
medline: 11 11 2020
Statut: epublish

Résumé

Mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that mediates phosphoinositide-3-kinase (PI3K)/AKT signalling. This pathway is involved in a plethora of cellular functions including protein and lipid synthesis, cell migration, cell proliferation and apoptosis. In this study, we proposed to delineate the role of mTORC1 in haemopoietic lineage commitment using knock out (KO) mouse and cell line models. Mx1-cre and Vav-cre expression systems were used to specifically target Raptor

Identifiants

pubmed: 31729420
doi: 10.1038/s41598-019-53141-1
pii: 10.1038/s41598-019-53141-1
pmc: PMC6858379
doi:

Substances chimiques

Biomarkers 0
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16917

Subventions

Organisme : Medical Research Council
ID : MR/K014854/1
Pays : United Kingdom

Références

Cancer Sci. 2009 May;100(5):970-7
pubmed: 19298223
Blood. 2011 Aug 25;118(8):2044-54
pubmed: 21613252
Nature. 2009 Apr 16;458(7240):904-8
pubmed: 19212321
Br J Haematol. 2016 Aug;174(3):461-9
pubmed: 27030515
Commun Biol. 2018 Apr 5;1:29
pubmed: 30271915
J Immunol. 2016 Sep 15;197(6):2250-60
pubmed: 27521345
Stem Cell Res. 2015 Nov;15(3):715-721
pubmed: 26599326
Blood. 2000 Oct 15;96(8):2641-8
pubmed: 11023493
Science. 2013 Aug 9;341(6146):670-3
pubmed: 23868921
Nat Cell Biol. 2017 Jun;19(6):626-638
pubmed: 28504707
Oncogene. 2010 Feb 18;29(7):1003-16
pubmed: 19935711
Blood. 2000 Mar 1;95(5):1652-5
pubmed: 10688820
Mol Cell Biol. 1998 Jan;18(1):102-9
pubmed: 9418858
Biosci Biotechnol Biochem. 2009 Jan;73(1):79-84
pubmed: 19129652
Blood. 2008 Oct 1;112(7):2750-60
pubmed: 18625885
Front Oncol. 2013 Jun 20;3:165
pubmed: 23802099
Sci Adv. 2018 Sep 12;4(9):eaar3938
pubmed: 30258985
Cell Stem Cell. 2018 Jun 01;22(6):879-892.e6
pubmed: 29804890
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Genes Dev. 1998 Aug 1;12(15):2403-12
pubmed: 9694804
Nature. 1992 Nov 19;360(6401):225-31
pubmed: 1359428
Blood. 2006 Jun 1;107(11):4308-16
pubmed: 16469877
Nephrol Dial Transplant. 2012 Feb;27(2):537-41
pubmed: 21785038
Cell. 1995 Oct 6;83(1):59-67
pubmed: 7553874
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10
pubmed: 10411939
Autophagy. 2016 Jun 2;12(6):936-48
pubmed: 27168493
Development. 2013 Jun;140(12):2463-7
pubmed: 23715539
Blood. 2008 Feb 1;111(3):1138-46
pubmed: 17934067
Haematologica. 2013 Sep;98(9):1353-8
pubmed: 23716557
J Clin Invest. 2012 Jun;122(6):2114-29
pubmed: 22622041
Blood. 2005 Aug 1;106(3):879-85
pubmed: 15831701
Haematologica. 2018 Oct;103(10):1593-1603
pubmed: 30076180
Blood. 2018 Jan 25;131(4):450-461
pubmed: 29101239
Sci Adv. 2018 Jan 31;4(1):eaar5701
pubmed: 29399633
Curr Opin Immunol. 2006 Apr;18(2):127-34
pubmed: 16464566
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8
pubmed: 8901585
Science. 2016 Jan 8;351(6269):aab2116
pubmed: 26541609
Immunity. 2007 Jun;26(6):715-25
pubmed: 17582344
Chem Biol Interact. 2014 Sep 5;220:269-77
pubmed: 25058688
Cell Stem Cell. 2012 Sep 7;11(3):429-39
pubmed: 22958934
Blood. 2016 Mar 10;127(10):1242-8
pubmed: 26787736
Cancer Res. 2006 Jan 1;66(1):527-34
pubmed: 16397269
Prog Mol Biol Transl Sci. 2014;124:155-88
pubmed: 24751430
Mol Cell Biol. 2005 Oct;25(19):8496-506
pubmed: 16166632
Elife. 2014 Sep 08;3:e01913
pubmed: 25201874
Crit Rev Biochem Mol Biol. 2003;38(1):61-88
pubmed: 12641343
Am J Hematol. 2014 Oct;89(10):954-63
pubmed: 24966026
Int J Oncol. 2000 Feb;16(2):339-45
pubmed: 10639579
Biochem Soc Trans. 2018 Oct 19;46(5):1313-1324
pubmed: 30154096
Cell Metab. 2008 Nov;8(5):411-24
pubmed: 19046572
Nat Immunol. 2013 Dec;14(12):1266-76
pubmed: 24141387

Auteurs

Natasha Malik (N)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Karen M Dunn (KM)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Jennifer Cassels (J)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Jodie Hay (J)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Christopher Estell (C)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Owen J Sansom (OJ)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, UK.

Alison M Michie (AM)

Institute of Cancer Sciences, College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Alison.Michie@glasgow.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH